AvanafilPDE5 inhibitor CAS# 330784-47-9 |
- NVP-BEP800
Catalog No.:BCC2129
CAS No.:847559-80-2
- BIIB021
Catalog No.:BCC2124
CAS No.:848695-25-0
- Retaspimycin
Catalog No.:BCC1889
CAS No.:857402-23-4
- IPI-504 (Retaspimycin hydrochloride)
Catalog No.:BCC2126
CAS No.:857402-63-2
- PF-04929113 (SNX-5422)
Catalog No.:BCC2130
CAS No.:908115-27-5
- 17-AAG Hydrochloride
Catalog No.:BCC1297
CAS No.:911710-03-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 330784-47-9 | SDF | Download SDF |
PubChem ID | 9869929 | Appearance | Powder |
Formula | C23H26ClN7O3 | M.Wt | 483.95 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 50 mg/mL (103.32 mM; Need ultrasonic) | ||
Chemical Name | 4-[(3-chloro-4-methoxyphenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide | ||
SMILES | COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCCC4CO)Cl | ||
Standard InChIKey | WEAJZXNPAWBCOA-INIZCTEOSA-N | ||
Standard InChI | InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Avanafil Dilution Calculator
Avanafil Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.0663 mL | 10.3316 mL | 20.6633 mL | 41.3266 mL | 51.6582 mL |
5 mM | 0.4133 mL | 2.0663 mL | 4.1327 mL | 8.2653 mL | 10.3316 mL |
10 mM | 0.2066 mL | 1.0332 mL | 2.0663 mL | 4.1327 mL | 5.1658 mL |
50 mM | 0.0413 mL | 0.2066 mL | 0.4133 mL | 0.8265 mL | 1.0332 mL |
100 mM | 0.0207 mL | 0.1033 mL | 0.2066 mL | 0.4133 mL | 0.5166 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Avanafil is a potent and selective inhibitor of phosphodiesterase type 5 (PDE5) with IC50 value of 5.2nM [1].
PDE5 is abundantly expressed in penile corpus cavernosum and regulates penile blood flow by regulating the cGMP concentration. PDE5 inhibitors are similar in structure to cGMP and competitively bind to PDE5, resulting in the inhibition of cGMP hydrolysis. Avanafil is a high selective inhibitor of PDE5 with Ki value of 4.3nM and is developed for the treatment of erectile dysfunction. It shows high selectivity against other PDE enzymes of the PDE family. In the intravenous study, the administration of avanafil at 300μg/kg can potentiate penile tumescence. The calculated ED200% of avanafil on tumescence is 37.5μg/kg and the plasma concentration is 59.6ng/ml. Additionally, avanafil potentiates penile tumescence at a dose range of 100 to 1,000μg/kg intraduodenally. And the ED200% is 151.7μg/kg [1, 2].
References:
[1] Kotera J, Mochida H, Inoue H, Noto T, Fujishige K, Sasaki T, Kobayashi T, Kojima K, Yee S, Yamada Y, Kikkawa K, Omori K. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol. 2012 Aug;188(2):668-74.
[2] Cui YS, Li N, Zong HT, Yan HL, Zhang Y. Avanafil for male erectile dysfunction: a systematic review and meta-analysis. Asian J Androl. 2014 May-Jun;16(3):472-7.
- Paclitaxel
Catalog No.:BCN4650
CAS No.:33069-62-4
- KH 7
Catalog No.:BCC7787
CAS No.:330676-02-3
- HCTU
Catalog No.:BCC2818
CAS No.:330645-87-9
- TCTU
Catalog No.:BCC2689
CAS No.:330641-16-2
- Peramivir
Catalog No.:BCC1846
CAS No.:330600-85-6
- H-Orn(Z)-OH
Catalog No.:BCC3003
CAS No.:3304-51-6
- Aloe-emodin-8-O-beta-D-glucopyranoside
Catalog No.:BCN1456
CAS No.:33037-46-6
- Boc-β-Ala-OH
Catalog No.:BCC3051
CAS No.:3303-84-2
- TC HSD 21
Catalog No.:BCC6228
CAS No.:330203-01-5
- SU6656
Catalog No.:BCC6392
CAS No.:330161-87-0
- Cyanidin-3-O-sambubioside chloride
Catalog No.:BCN3150
CAS No.:33012-73-6
- ent-16beta,17-Dihydroxy-19-kauranoic acid
Catalog No.:BCN1457
CAS No.:3301-61-9
- PCI 29732
Catalog No.:BCC4100
CAS No.:330786-25-9
- MRT 10
Catalog No.:BCC7950
CAS No.:330829-30-6
- Amitraz
Catalog No.:BCC8816
CAS No.:33089-61-1
- Betrixaban
Catalog No.:BCC5118
CAS No.:330942-05-7
- AS 1269574
Catalog No.:BCC7878
CAS No.:330981-72-1
- Caffeic acid
Catalog No.:BCN5979
CAS No.:331-39-5
- IQ 1
Catalog No.:BCC7965
CAS No.:331001-62-8
- PT 1
Catalog No.:BCC7846
CAS No.:331002-70-1
- Stephavanine
Catalog No.:BCN5253
CAS No.:33116-33-5
- BAM7
Catalog No.:BCC1397
CAS No.:331244-89-4
- LG 101506
Catalog No.:BCC7696
CAS No.:331248-11-4
- Boc-D-Phg-OH
Catalog No.:BCC3315
CAS No.:33125-05-2
Avanafil for the treatment of erectile dysfunction.[Pubmed:27416913]
Expert Rev Clin Pharmacol. 2016 Sep;9(9):1163-70.
INTRODUCTION: Erectile dysfunction (ED) affects millions of men worldwide, and the incidence of ED will continue to increase as the aging population grows. The first generation of phosphodiesterase-5 (PDE5) inhibitors, the mainstay of oral ED therapy, has revolutionized the treatment of this condition, but not without some drawbacks. Avanafil, the only United States and European Union-approved second-generation PDE5 inhibitor, is a safe and efficacious alternative to its predecessors. AREAS COVERED: We reviewed the current and most up-to-date literature regarding Avanafil, as well as the pivotal trials that measured efficacy and tolerability. As Avanafil is still a relatively new drug, there is still a relative paucity of literature which inherently limited the search parameters. We searched the PUBMED database for articles detailing the clinical trials, chemistry, pharmacokinetics and dynamics, safety, and efficacy of the drug. Expert commentary: Avanafil's unique pharmacologic profile both narrows and minimizes side effects while reducing the time of onset of action to half of its closest competitor, providing men who suffer with ED a return to a more spontaneous sex life.
Effects of different combinations of nanocrystallization technologies on avanafil nanoparticles: in vitro, in vivo and stability evaluation.[Pubmed:27939570]
Int J Pharm. 2017 Jan 30;517(1-2):148-156.
The study investigated the effects of different combined top-down and bottom-up nanocrystallization technologies on particle size and solid state of Avanafil nanoparticles. Combined antisolvent precipitation-ultrasonication (sonoprecipitation) technique was adopted to prepare 18 formulas according to 3(2).2(1) factorial design using 3 stabilizers; Tween 80, polyvinyl alcohol (PVA) and Pluronic F68 at different concentrations with different cryoprotectants. Particle size analysis of the lyophilized formulas showed that Tween 80 was an effective nanoparticles stabilizer in contrast to Pluronic F68 and PVA which failed to prevent nanoparticles flocculation when they were used at high concentration. The combined effects of nanonization and amorphism contributed to the improvement in solubility. Further processing of the sonoprecipitated formulas by high pressure homogenization (HPH) (modified NANOEDGE technology) resulted in further size reduction of PVA-stabilized particles, while it stimulated flocculation of Tween-stabilized nanoparticles. Nevertheless, all of the homogenized formulas partially retrieved their crystallinity which reduced their solubility. Non-homogenized formula 2E composed of 1:2 (Avanafil: Tween) with glucose as cryoprotectant, exhibited 13.68- and 2.59-fold improvement in solubility and in vitro dissolution, respectively. This formula had oral bioavailability of 137.02% relative to Spedra((R)) tablets and it maintained its nanosize, amorphism and dissolution behavior over 6 months of storage under stress conditions.
Formulation of avanafil in a solid self-nanoemulsifying drug delivery system for enhanced oral delivery.[Pubmed:27590128]
Eur J Pharm Sci. 2016 Oct 10;93:447-55.
Avanafil was incorporated into solid self-nanoemulsifying systems with the aim of improving its oral bioavailability. Labrafil, Labrafac, and Miglyol 812 N were investigated as oils, Tween 80 and Cremophor EL as surfactants, and Transcutol HP as a co-surfactant. Nine formulations produced clear solutions of 13.89-38.09nm globules after aqueous dilution. Adsorption of preconcentrate onto Aeroperl 300 Pharma at a 2:1 ratio had no effect on nanoemulsion particle size. Differential scanning calorimetry, X-ray diffraction, and scanning electron microscopy indicated that Avanafil was molecularly dispersed within the solid nanosystems. A formulation containing 10% Labrafil, 60% Tween 80, and 30% Transcutol HP had the highest drug loading (44.48mg/g) and an acceptable in vitro dissolution profile (96.42% within 30min). This formulation was chemically and physically stable for 6months under accelerated storage conditions and it produced a 3.2-fold increase in bioavailability in rabbits, as compared to conventional commercially available Avanafil tablets (Spedra((R))).
Effect of different polymers on avanafil-beta-cyclodextrin inclusion complex: in vitro and in vivo evaluation.[Pubmed:27576665]
Int J Pharm. 2016 Oct 15;512(1):168-177.
In this study, we examined the effect of different polymers on the chemical, physical and pharmacokinetic properties of Avanafil-beta-cyclodextrin (beta-CD) inclusion complex. Equimolar mixtures of drug and beta-CD were used to prepare 25 ternary drug-beta-CD-polymer inclusion complexes using five different polymers, polyethylene glycol (PEG 4000), polyvinyl pyrrolidone (PVP K-30), chitosan, hydroxypropylmethyl cellulose, and hydroxyethyl cellulose, each in five different concentrations, 1, 3, 5, 7, and 10% (w/w). The addition of 10% (w/w) PEG 4000 resulted in a significant decrease of drug solubility, where the infrared spectra and differential scanning thermograms revealed an interaction between PEG 4000 and Avanafil which hindered drug inclusion. In contrast, addition of 7% (w/w) PVP K-30 facilitated drug inclusion as concluded from differential scanning thermograms, X-ray diffraction patterns and scanning electron micrographs. This resulted in a subsequent improvement in drug solubility and in vitro dissolution. This formula was chemically and physically stable for 6 months under accelerated storage conditions. The formula had a relative bioavailability of 125.56% in rabbits as compared to conventional commercially available Avanafil tablets (Spedra((R))).